Dina El-Rayes

Dr. Dina El-Rayes


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
VPVenkata Sai Usha Sri Polaki
Venkata Sai Usha Sri Polaki
TGTrey E. Gilpin
Trey E. Gilpin
APApoorva T. Patil
Apoorva T. Patil
ECEmily Chiu
Emily Chiu
RBRuth Baker
Ruth Baker
DMDaniel R. Matson
Daniel R. Matson
BACKGROUND: A priori knowledge of recurrence risk in patients with nonmetastatic (International Federation of Gynecology and Obstetrics [FIGO] stage I) uterine serous carcinoma (USC) would enable a risk-stratified approach to the use of adjuvant chemotherapy. This would greatly reduce treatment-related morbidity and be predicted to improve survival. METHODS: GATA2 expression was scored by IHC across a retrospective multiinstitutional cohort of 195 primary USCs. Associations between GATA2 levels and clinicopathologic metrics were evaluated using Student’s t test, Fisher’s exact test, Kaplan-Meier method, and Cox proportional hazard ratio. Invasion in patient-derived USC cells was assessed by Student’s t test. RNA-Seq, anti-GATA2 ChIP-Seq, and confirmatory Western blotting enabled identification of GATA2 targets. RESULTS: Patients with FIGO stage I GATA2 hi USCs had 100% recurrence-free and 100% cancer-related survival, which was significantly better than patients with GATA2 lo USCs. In patients for whom adjuvant chemotherapy was omitted, patients with GATA2 hi USC had 100% recurrence-free 5-year survival compared with 60% recurrence-free survival in patients with GATA2 lo USC. Depletion of GATA2 in patient-derived USC cells increased invasion in vitro. CONCLUSION: Routine GATA2 IHC identifies 33% of patients with FIGO stage I USC who have a greatly reduced risk of posthysterectomy USC recurrence. Our results suggest that a GATA2-guided personalized medicine approach could be rapidly implemented in most hospital settings, would reduce treatment-related morbidity, and would likely improve outcomes in patients with USC. FUNDING: NIH grants R01 DK068634, P30 CA014520, S10 OD023526, K08 DK127244, T32 HL007899, the UW-Madison Department of Pathology and Laboratory Medicine, the UW-Madison Centennial Scholars Program, the Diane Lindstrom Foundation, the American Cancer Society, the V Foundation, The Hartwell Foundation, and the UMN Department of Obstetrics, Gynecology, and Women’s Health.

10 April 2025 in Dermatopathology
Verified
Journal Article
Open access
PDF file
DEDina El-Rayes
Dina El-Rayes
KWKatlin Taylor Wilson
Katlin Taylor Wilson
SMSheilagh Maguiness
Sheilagh Maguiness
DMDaniel D. Miller
Daniel D. Miller
Gerardo CazzatoGerardo Cazzato
Gerardo Cazzato
Alessio GiubellinoAlessio Giubellino
Alessio Giubellino
Congenital melanocytic nevi (CMN) are benign tumors present at birth or arising in the first few months of life. A small subset of these nevi present with mild atypical features and heterogeneous differentiation, including Schwannian differentiation. We present a case of a 3-week-old with a 7 cm red/purple scalp nodule consistent with CMN with mild atypical heterogeneous areas. On histology, there were dermal nests of spindle cells in a fibrillar matrix, with increased vessels and clusters of small round melanocytes interspersed between collagen bundles and around adnexal structures. The lesion also exhibited rare pagetoid ascent of melanocytes as single cells and nests. Overall, these features were consistent with a CMN with nodular proliferative neurocristic cutaneous hamartoma (NCH) with a component of a compound mild atypical melanocytic proliferation. Next generation sequencing (NGS) identified a novel SH2B1::BRAF fusion. This case highlights the diagnostic challenges of heterogeneous differentiation within CMN in young children.